P-296 - Preventive intraperitoneal chemotherapy in colon cancers with high risk of recurrence: outcome at 5 years from a prospective study

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Presenter M. Abid
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors M. Abid
  • Centre Anti-Cancer Batna, Batna/DZ



The study evaluated the effectiveness of adjuvant immediate postoperative intraperitoneal chemotherapy (IPIPC), in the prevention of local and peritoneal recurrence in colon cancer at high risk of recurrence and the 5-year survival.


After surgical resection, 105 patients considered in preoperative or intraoperative period at high risk of peritoneal recurrence (CT3/T4, tumor perforation, localized carcinomatosis, ovarian damage, bowel obstruction, positive extemporaneous intraoperative cytology) were randomized after radical surgical resection in two groups. The first group (n = 53) received from postoperative D1 to D5, intraperitoneal chemotherapy with mitomycin C (D0: 10 to 15 mg/m2) and 5-fluorouracil (D1 - D4: 650 mg/m2). In the second group (n = 52), only curative surgical resection was performed.


Local or peritoneal recurrence has been observed in 4 cases (7.6%) in the group whom received intraperitoneal chemotherapy against 14 cases (26.9%) in the second group (p = 0. 008 s). In the postoperative period, ranging from D0 to D30, 7 patients died within the two groups. Immediate intraperitoneal chemotherapy was associated with a mortality 3 times higher than for the control group: 5 patients (9.4%) in the group treated with intraperitoneal chemotherapy against 2 patients (3.8%) in the control group. This difference was not significant (P = 0, 25 ns). The 5-year survival is about 54.7 months for Group 1 against 48.7 months in the control group (P = 0. 812 ns).


In this study, adjuvant intraperitoneal chemotherapy in colon cancer with high risk of recurrence has led a significant reduction in the rate of local and peritoneal recurrence but doesn't really increase the 5-year survival.